BioTech 365

MAY 12, 2021

ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement License agreement to enhance GenScript’s CRISPR offering for gene and cell therapy research DUBLIN & PISCATAWAY, N.J.–(BUSINESS

Genome 52

Genome Genomics Licensing Licensing 52

BioTech 365

APRIL 19, 2021

ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement CRISPR offerings to enhance NUVISAN’s drug development service portfolio DUBLIN & BERLIN–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide broad access … Continue reading →

Genome 52

Genome Genomics Licensing Licensing 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. This is really what has been very challenging for upscaling viral vector production and what leads some companies that have in-licensed projects with a huge amount of viral vector to slightly panic about future production,” she says.

Genome 244

Genome Genomics Medicine Gene Therapy 244

BioTech 365

MARCH 9, 2021

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models DUBLIN & TOKUSHIMA, Japan–(BUSINESS WIRE)–ERS … Continue reading →

Genome 52

Genome Genomics Licensing Licensing 52

Pharma Times

JANUARY 17, 2024

License agreement concerns development of cell therapies for corneal blindness

Genome 110

Genome Genomics Licensing Licensing 110

BioTech 365

FEBRUARY 23, 2021

ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →

Life Science 52

Life Science Genome Genomics Licensing 52

The Pharma Data

NOVEMBER 30, 2020

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. “The

Genome 52

Genome Genomics Licensing Licensing 52

BioSpace

DECEMBER 11, 2023

Backed by ARCH Venture Partners and Fujifilm, as well as technology licensed from MIT, Tome is looking to create curative cell and integrative gene therapies.

Gene Therapy 117

Gene Therapy Genome Genomics Medicine 117

Drug Discovery World

JANUARY 17, 2024

ERS Genomics, a CRISPR/Cas9 licensing company, and StemSight, a biotechnology company developing stem cell based therapies for corneal blindness, have entered a non-exclusive CRISPR/Cas9 license agreement. The company provides licensing for companies interested in pursuing CRISPR/Cas9’s use in their commercial programmes.

Licensing 52

Licensing Licensing Genome Genomics 52

BioPharma Reporter

DECEMBER 3, 2020

ERS Genomics, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by the one of the joint 2020 Nobel Prize winners for Chemistry, Dr Emmanuelle Charpentier, has granted a non-exclusive license agreement to German startup, Vivlion.

Licensing 64

Licensing Licensing Genome Genomics 64

BioSpace

SEPTEMBER 8, 2021

based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans. Durham, N.C.-based

Genome 81

Genome Genomics Licensing Licensing 81

BioTech 365

MARCH 1, 2021

ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development Jon Kratochvil joins as Vice President for Business Development & Licensing for North America … Continue reading →

Business Development 52

Business Development Genome Genomics Development 52

BioTech 365

OCTOBER 13, 2020

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genome 52

Genome Genomics Reagent Gene Editing 52

Drug Discovery World

MARCH 25, 2024

Allogene Therapeutics and Arbor Biotechnologies Biotechnology companies Allogene Therapeutics and Arbor Biotechnologies entered a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s AlloCAR T platform for the treatment of autoimmune disease (AID).

Gene Editing 52

Gene Editing Drugs Genome Genomics 52

Drug Discovery Today

APRIL 22, 2020

Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license (..)

Licensing 40

Licensing Licensing Genome Genomics 40

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

pharmaphorum

MARCH 24, 2022

LifeMine has developed an industrialised, genomics-based discovery engine that it hopes will take a broad, systematic approach to identifying new compounds from fungi and screening them for activity against disease targets. Image by jggrz from Pixabay . The post GSK partners LifeMine on fungi-derived medicines appeared first on.

Medicine 87

Medicine Genome Genomics Engineer 87

Pharmaceutical Technology

JULY 22, 2022

In 2020, Sangamo and Novartis signed an exclusive, global licensing collaboration agreement to develop and commercialise genomic therapies for the treatment of neurodevelopmental disorders, including autism. The post Sangamo’s cell therapy receives EC orphan medicinal product designation appeared first on Pharmaceutical Technology.

Medicine 130

Medicine Production Genome Genomics 130

Drug Discovery World

SEPTEMBER 6, 2023

A new licensing agreement between Vita Therapeutics and MilliporeSigma (the US and Canada Life Science business of Merck) will see Vita leverage MilliporeSigma’s foundational CRISPR patents to advance its preclinical asset VTA-100 for limb-girdle muscular dystrophy (LGMD2A).

Genome 52

Genome Genomics Gene Life Science 52

Drug Discovery World

AUGUST 21, 2023

Transcription factors are proteins that control every gene in a person’s genome by binding to DNA and flipping the on/off switches that govern gene expression. Talus Bio was also awarded a $2.0M When they go awry, they often drive cancer and other disease processes like diabetes, inflammatory diseases, and neurological conditions.

Drugs 98

Drugs Gene Expression Protein Gene 98

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA. The system comprises the Cas9 enzyme and a guide RNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

The Pharma Data

JANUARY 12, 2021

Boehringer Ingelheim has announced it has signed a collaboration and licensing deal with Enara Bio to advance novel targeted cancer immunotherapies. Dark Antigens are in reference to a newer class of cancer antigens derived from a portion of the human genome not normally expressed as a protein. Michael Vi/Shutterstock.

Research 52

Research Genome Genomics Licensing 52

Drug Discovery World

MAY 5, 2023

The deal also provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs). “We We are excited to bring this powerful platform into Eterna.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Drug Discovery World

MARCH 27, 2023

Ono will have an exclusive option to license global rights to the candidates for further development and commercialisation. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest using its ENIGMACTM macrophage drug discovery platform.

Drugs 52

Drugs Antibody Genome Genomics 52

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. Under the agreement, Boehringer Ingelheim has the option to license dark antigens discovered and validated by Enara Bio.

Genome 56

Genome Genomics Licensing Licensing 56

BioTech 365

SEPTEMBER 29, 2020

NEW YORK, LONDON, & PARIS–(BUSINESS WIRE)–#biopharmaceutical–Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum (..)

Licensing 52

Licensing Licensing Genome Genomics 52

pharmaphorum

DECEMBER 22, 2020

The latest deals include a license agreement with San Diego-based Ligand Therapeutics , which has a subsidiary producing technology for neurological disorders. The license agreement, together with the biotech’s cash reserves, is enough to fund operations through 2023.

Licensing 52

Licensing Licensing Genetics Sales 52

pharmaphorum

DECEMBER 2, 2021

GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the discovery of new medicines. Most notable is GSK’s $700 million upfront deal in the summer to license two drugs for neurological disease developed by US biotech Alector.

Biobanking 66

Biobanking Genome Genomics Genetics 66

pharmaphorum

JANUARY 5, 2023

and OriCiro Genomics K.K. Nonetheless, Moderna has previously been involved in licensing deals to advance its technology. Biotech Moderna, Inc. have announced they have entered into a definitive agreement for Moderna to acquire OriCiro at a cost of $85 million. The deal marks 10-year-old Moderna’s first acquisition.

Gene Sequencing 75

Gene Sequencing DNA Vaccination Vaccine 75

Drug Discovery World

MARCH 6, 2024

Guiding neurological drug discovery and development to success The 20 years since the Human Genome Project has seen transformational advances in the molecular understanding of cancers and rare genetic diseases, leading to genetically informed, personalised selection of therapies and massively improved outcomes for many patients.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

pharmaphorum

MARCH 25, 2021

The COSMIC (Catalogue of Somatic Mutations in Cancer) database, operated by the Wellcome Sanger Institute, grew out of the work of the Cancer Genome Project and has been gathering data on mutations associated with specific cancers for almost 17 years.

Drugs 57

Drugs Genome Project Genome Genomics 57

pharmaphorum

DECEMBER 5, 2022

That sets up a rolling Biologics License Application (BLA) with the FDA by the end of the year, setting Valneva on course to bring the first chikungunya vaccine to market anywhere in the world. Valneva estimates that the global market for vaccines against chikungunya could exceed $500 million annually by 2032.

Vaccination 94

Vaccination Vaccine Antibody Allergies 94

Camargo

NOVEMBER 11, 2020

Unpacking the (Black) Box: Antares Licenses Urology Product with Boxed Warning. In October, Antares Pharma licensed Ferring Pharmaceuticals’ Nocdurna® (desmopressin acetate) sublingual tablet , which was approved in 2018 for the same indication as Noctiva and has a boxed warning highlighting the same risks.

Development 242

Development Bioequivalency Generic Drugs Production 242

pharmaphorum

OCTOBER 1, 2021

It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document. Chief technology officer Clive Brown is also sitting on a £10 million stake. The post Oxford Nanopore makes stellar debut on UK stock market appeared first on.

Marketing 52

Marketing Business Development Genome Genomics 52

The Pharma Data

JUNE 7, 2023

. “Complementing in-house expertise with external collaboration continues to be a priority in areas of high unmet medical need where insufficient, or no treatment options are currently available,” said Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. Financial details of the agreement were not disclosed.

Drugs 52

Drugs Gene Editing Genome Genomics 52